Speaker illustration

Doctor Phillip Hunt

AstraZeneca, Gaithersburg (United States of America)

Director, Epidemiology for cardiovascular, renal, and metabolic (CVRM) indications with a current focus on heart failure. Fifteen years of experience in design and execution of epidemiologic studies and statistical analysis in large health care data sets (claims, EMR, registries) for research in pharmacoepidemiology, public health, and occupational health surveillance. Prior to embracing pharmacoepidemiology, 15 years of consulting, teaching, and research experience in occupational, environmental, and public health, including helping to clean up hazardous waste sites, Love Canal being the most notorious.

Describing patient characteristics and the incidence and prevalence of heart failure in Germany: a retrospective database study using AOK Plus - part of the HF-BoI Project

Event: Heart Failure 2021 Online Congress

Topic: Epidemiology, Prognosis, Outcome

Session: ePoster session

Thumbnail

Heart-Failure related hospitalisations and cardiovascular events among patients with incident heart failure in Germany: a retrospective cohort study using AOK PLUS data - part of the HF-BoI Project

Event: Heart Failure 2021 Online Congress

Topic: Epidemiology, Prognosis, Outcome

Session: ePoster session

Thumbnail

Healthcare related resource use and costs among patients with new diagnosis of Heart Failure in Germany: a retrospective cohort study using AOK PLUS data - part of the HF-BoI Project

Event: Heart Failure 2021 Online Congress

Topic: Treatment

Session: ePoster session

Thumbnail

This platform is supported by

logo Novo Nordisk